Arvinas Inc (ARVN) - Net Assets
Based on the latest financial reports, Arvinas Inc (ARVN) has net assets worth $433.90 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($717.90 Million) and total liabilities ($284.00 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Arvinas Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $433.90 Million |
| % of Total Assets | 60.44% |
| Annual Growth Rate | 37.92% |
| 5-Year Change | -44.49% |
| 10-Year Change | N/A |
| Growth Volatility | 17432.58 |
Arvinas Inc - Net Assets Trend (2016–2025)
This chart illustrates how Arvinas Inc's net assets have evolved over time, based on quarterly financial data. Also explore how large is Arvinas Inc's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Arvinas Inc (2016–2025)
The table below shows the annual net assets of Arvinas Inc from 2016 to 2025. For live valuation and market cap data, see Arvinas Inc (ARVN) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $433.90 Million | -22.75% |
| 2024-12-31 | $561.70 Million | -14.89% |
| 2023-12-31 | $660.00 Million | +16.83% |
| 2022-12-31 | $564.90 Million | -27.73% |
| 2021-12-31 | $781.70 Million | +21.72% |
| 2020-12-31 | $642.20 Million | +183.30% |
| 2019-12-31 | $226.69 Million | +65.87% |
| 2018-12-31 | $136.67 Million | +55485.06% |
| 2017-12-31 | $245.87K | -98.98% |
| 2016-12-31 | $24.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Arvinas Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 157860224000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $100.00K | 0.02% |
| Other Comprehensive Income | $1.20 Million | 0.28% |
| Other Components | $2.04 Billion | 471.31% |
| Total Equity | $433.90 Million | 100.00% |
Arvinas Inc Competitors by Market Cap
The table below lists competitors of Arvinas Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Advanced Nano Products Co. Ltd
KQ:121600
|
$672.32 Million |
|
MTY Food Group Inc
TO:MTY
|
$672.49 Million |
|
Sichuan Goldstone Orient New Material Equipment Co Ltd
SHE:300434
|
$672.53 Million |
|
Jinling Pharmaceutical Co Ltd
SHE:000919
|
$672.54 Million |
|
Bank Bukopin Tbk
JK:BBKP
|
$671.50 Million |
|
BridgeBio Oncology Therapeutics, Inc.
NASDAQ:BBOT
|
$671.48 Million |
|
Fujian Rongji Software Co Ltd
SHE:002474
|
$671.02 Million |
|
Sichuan Kexin Mechanic Electric
SHE:300092
|
$671.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Arvinas Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 561,700,000 to 433,900,000, a change of -127,800,000 (-22.8%).
- Net loss of 80,800,000 reduced equity.
- Share repurchases of 91,900,000 reduced equity.
- Other comprehensive income increased equity by 200,000.
- Other factors increased equity by 44,700,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-80.80 Million | -18.62% |
| Share Repurchases | $91.90 Million | -21.18% |
| Other Comprehensive Income | $200.00K | +0.05% |
| Other Changes | $44.70 Million | +10.3% |
| Total Change | $- | -22.75% |
Book Value vs Market Value Analysis
This analysis compares Arvinas Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.57x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 7.82x to 1.57x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $1.34 | $10.51 | x |
| 2017-12-31 | $0.01 | $10.51 | x |
| 2018-12-31 | $4.32 | $10.51 | x |
| 2019-12-31 | $6.88 | $10.51 | x |
| 2020-12-31 | $16.24 | $10.51 | x |
| 2021-12-31 | $15.63 | $10.51 | x |
| 2022-12-31 | $10.62 | $10.51 | x |
| 2023-12-31 | $11.89 | $10.51 | x |
| 2024-12-31 | $7.81 | $10.51 | x |
| 2025-12-31 | $6.69 | $10.51 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Arvinas Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -18.62%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -30.77%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.65x
- Recent ROE (-18.62%) is above the historical average (-1009.74%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -59.72% | -215.18% | 0.18x | 1.58x | $-16.75 Million |
| 2017 | -9781.27% | -317.32% | 0.11x | 271.89x | $-24.07 Million |
| 2018 | -30.35% | -289.59% | 0.07x | 1.46x | $-55.15 Million |
| 2019 | -27.41% | -144.57% | 0.14x | 1.33x | $-84.80 Million |
| 2020 | -17.41% | -512.74% | 0.03x | 1.12x | $-176.01 Million |
| 2021 | -23.44% | -392.29% | 0.03x | 2.02x | $-261.37 Million |
| 2022 | -48.13% | -206.93% | 0.10x | 2.25x | $-328.39 Million |
| 2023 | -55.65% | -467.90% | 0.06x | 1.98x | $-433.30 Million |
| 2024 | -35.41% | -75.51% | 0.24x | 1.94x | $-255.07 Million |
| 2025 | -18.62% | -30.77% | 0.37x | 1.65x | $-124.19 Million |
Industry Comparison
This section compares Arvinas Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Arvinas Inc (ARVN) | $433.90 Million | -59.72% | 0.65x | $672.23 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Arvinas Inc
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing… Read more